GANX

Gain Therapeutics Inc.

Price

$1.79

return (12m)

13.29%

p/e

-3.82

p/bv

6.80

DIVIDEND YIELD

0.00%

GANX price

Gain Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment GANX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-11.17%

3 months

-4.79%

1 year

13.29%

2 years

19.73%

5 years

-74.47%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals GANX

Valuation

P/E

-3.82

Sector -3.50

Industry -3.50

P/BV

6.80

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector 2.01

Industry 2.01

EV/EBITDA

-13.73

Sector -214.99

Industry -214.99

EV/EBIT

-13.65

Sector -47.59

Industry -47.59

P/EBITDA

-4.00

Sector -21.41

Industry -21.41

P/EBIT

-3.98

Sector -28.65

Industry -28.65

P/Total Assets

4.98

Sector 1.19

Industry 1.19

P/Net Current Assets

7.08

Sector -11.97

Industry -11.97

P/Working Capital

6.65

Sector -167.95

Industry -167.95

EPS

-0.47

Sector -1.81

Industry -1.81

BVPS

0.26

Sector 2.06

Industry 2.06

Efficiency

Gross Margin

0.00%

Sector 41.30%

Industry 41.30%

EBITDA Margin

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

Sector -4,185,659.35%

Industry -4,185,659.35%

Operating Margin

0.00%

Sector -35.21%

Industry -35.21%

Net Profit Margins

0.00%

Sector -35.91%

Industry -35.91%

Asset Turnover

0.00

Sector 0.02

Industry 0.02

Profitability

ROE

-178.06%

Sector -56.04%

Industry -56.04%

ROA

-130.38%

Sector -60.31%

Industry -60.31%

ROIC

-2,408.75%

Sector -2,335.95%

Industry -2,335.95%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

4.36

Sector 2.89

Industry 2.89

Net Debt / EBITDA

2.76

Sector -14,066,680.10

Industry -14,066,680.10

Net Debt / EBIT

2.75

Sector -8.06

Industry -8.06

Net Debt / Equity

-1.14

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

0.02

Sector -0.85

Industry -0.85

Equity/Assets

0.73

Sector 0.46

Industry 0.46

Liabilities/Assets

0.27

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

7.68%

Sector -

Industry -

Fundamentals GANX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
GANX Gain Therapeutics Inc.	$1.79	13.29%	0.00%	-3.82	6.80	-178.06%	0.00%
JNJ Johnson & Johnson	$269.33	55.44%	1.96%	30.82	7.63	24.76%	21.48%
PFE Pfizer Inc.	$27.49	22.33%	6.26%	35.85	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$263.93	23.34%	2.59%	73.99	-78.76	-106.44%	9.81%
NVO Novo Nordisk A/S	$43.19	-26.70%	4.29%	10.56	5.61	53.11%	35.32%
MRK Merck & Co. Inc.	$146.11	87.14%	2.31%	113.21	8.55	7.55%	4.76%
AZN AstraZeneca PLC	$166.35	9.78%	1.94%	19.88	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$62.71	43.77%	4.04%	13.67	5.68	41.55%	18.85%
ZTS Zoetis Inc.	$72.66	-49.60%	2.88%	11.47	9.64	84.02%	27.77%
AMGN Amgen Inc.	$383.04	43.28%	2.60%	23.66	17.70	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$784.44	31.54%	0.47%	18.63	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$111.35	46.87%	0.00%	31.57	90.97	288.13%	24.86%
MCK McKesson Corporation	$874.67	27.00%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$506.08	30.72%	0.00%	29.15	6.34	21.76%	35.00%
CAH Cardinal Health Inc.	$224.45	52.89%	0.91%	30.53	-19.32	-63.29%	0.68%
ARGX argenx SE	$994.44	35.42%	0.00%	2.24	2.63	117.11%	44.68%
HRMY Harmony Biosciences Holdings Inc.	$42.23	31.71%	0.00%	13.50	2.45	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

GANX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Gain Therapeutics

Gain Therapeutics Inc.

Average Investor10 user rating

4.0 (1 people)

United States

6 years

Founded: 2020

2021

Time since IPO - 5 years

14

Employees

Gain Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $76.75 million, with shareholders equity totaling $11.29 million.

The company employs approximately 14 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Gain Therapeutics Inc. reported $- in revenue, generating net income of $-20.11 million.

Key financial metrics include a P/E ratio of -3.82, a price-to-book (P/B) ratio of 6.80, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker GANX.

Market cap

$76.75 million

Net worth

$11.29 million

$11,292,000.00

Assets

$15.42 million

$15,422,000.00

Total Shares Outstanding

42.88 million

42,879,000

Average Daily Trading Volume

$485.77 Thousand

$485,771.44

Sector

Health Care

Industry

Biotechnology

GANX

GANX revenue and profits

Financial Results GANX

DRAG THE FRAME TO SEE MORE DATA

GANX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$874.67 25,76% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$224.45 51,61% (12M)

P/E

30.53

0.91%

ROE

-63.29%

P/BV

-19.32

JNJ - Johnson & Johnson

$269.33 56,33% (12M)

P/E

30.82

1.96%

ROE

24.76%

P/BV

7.63

ABBV - AbbVie

$263.93 22,42% (12M)

P/E

73.99

2.59%

ROE

-106.44%

P/BV

-78.76

MRK - Merck & Co.

$146.11 85,19% (12M)

P/E

113.21

2.31%

ROE

7.55%

P/BV

8.55

AZN - AstraZeneca

$166.35 9,17% (12M)

P/E

19.88

1.94%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$27.49 22,43% (12M)

P/E

35.85

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$874.67 25,76% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$224.45 51,61% (12 M)

P/L

30.53

0.91%

ROE

-63.29%

P/VP

-19.32

JNJ - Johnson & Johnson

$269.33 56,33% (12 M)

P/L

30.82

1.96%

ROE

24.76%

P/VP

7.63

ABBV - AbbVie

$263.93 22,42% (12 M)

P/L

73.99

2.59%

ROE

-106.44%

P/VP

-78.76

MRK - Merck & Co.

$146.11 85,19% (12 M)

P/L

113.21

2.31%

ROE

7.55%

P/VP

8.55

AZN - AstraZeneca

$166.35 9,17% (12 M)

P/L

19.88

1.94%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$27.49 22,43% (12 M)

P/L

35.85

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Gain Therapeutics (GANX) today?

A cotação de Gain Therapeutics (GANX) hoje está em US$ 1.79, com uma variação de 13.29% em relação ao último ano. A cotação de Gain Therapeutics (GANX) iniciou o ano negociando na casa dos US$ 3.22 e hoje está em US$ 1.79. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Gain Therapeutics (GANX) e dados de ações do Ibovespa e mercados internacionais.

Quando Gain Therapeutics (GANX) paga dividendos?

Gain Therapeutics (GANX) não distribuiu dividendos no último ano.

Is Gain Therapeutics (GANX) a good investment?

Atualmente, Gain Therapeutics (GANX) está cotada a US$ 1.79, com um P/L de -3.82, representando um desvio de -335% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 13.29 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 13.29%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Gain Therapeutics (GANX) stock?

Investir em ações de Gain Therapeutics (GANX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Gain Therapeutics (GANX) yield today?

A rentabilidade de Gain Therapeutics (GANX) foi de -11.17% no último mês, 13.29% no último ano e -74.47% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Gain Therapeutics (GANX) hoje, o investimento total seria de US$ 179.00, com base na cotação atual de US$ 1.79.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 202.79
Em 5 anos: US$ 45.70
Em 10 anos: US$ 179.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

GANX

Gain Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment GANX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING GANX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Gain Therapeutics

Gain Therapeutics Inc.

United States

6 years

2021

14

PROFIT X PRICE GANX

Financial Results GANX

GANX cash flow

Asset, Revenue and Profit Growth - GANX

GANX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions